Research programme: PI3K-alpha inhibitors - Immuneering
Alternative Names: PI3K-alpha programme - ImmueneeringLatest Information Update: 20 Apr 2022
At a glance
- Originator Immuneering
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 Mar 2022 Early research in Cancer in USA (unspecified route) (Immuneering pipeline, March 2022)